{"analyses":[{"ciLowerLimit":"79.8","ciPctValue":"95","ciUpperLimit":"90.1","estimateComment":"95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Cumulative probability","paramValue":"85.8","testedNonInferiority":false},{"ciLowerLimit":"85.9","ciPctValue":"95","ciUpperLimit":"94.5","estimateComment":"95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Cumulative probability","paramValue":"91.1","testedNonInferiority":false},{"ciLowerLimit":"79.9","ciPctValue":"95","ciUpperLimit":"90.2","estimateComment":"95% confidence interval for the cumulative probability of completing the study without prostate specific antigen failure from Day 0 to Day 364.","groupIds":["OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Cumulative probability","paramValue":"85.9","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Day 0-28 (patients at risk=193, 201, 194)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Day 0-56 (patients at risk=192, 197, 192)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Day 0-84 (patients at risk=190, 193, 190)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}],"title":"Day 0-112 (patients at risk=190, 189, 188)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"}]}],"title":"Day 0-140 (patients at risk=187, 187, 182)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"}]}],"title":"Day 0-168 (patients at risk=179, 185, 180)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"11"}]}],"title":"Day 0-196 (patients at risk=173, 181, 175)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"}]}],"title":"Day 0-224 (patients at risk=168, 175, 173)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"14"}]}],"title":"Day 0-252 (patients at risk=165, 169, 168)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"18"}]}],"title":"Day 0-280 (patients at risk=157, 165, 163)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"21"}]}],"title":"Day 0-308 (patients at risk=153, 161, 156)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"24"}]}],"title":"Day 0-336 (patients at risk=149, 156, 150)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"26"}]}],"title":"Day 0-364 (patients at risk=149, 155, 148)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"202"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"201"}],"units":"Participants"}],"description":"The time to prostate specific antigen failure was defined as the days from first dosing (scheduled dosing days) where an increase in serum prostate specific antigen of ≥50% from nadir and a least 5 ng/mL measured on two consecutive occasions at least two weeks apart was noted.","groups":[{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days.","id":"OG000","title":"Degarelix 240/160 mg"},{"description":"Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days.","id":"OG001","title":"Degarelix 240/80 mg"},{"description":"Lupron Depot 7.5 mg IM (in the muscle) every 28 days starting at day 0.","id":"OG002","title":"Leuprolide 7.5 mg"}],"paramType":"NUMBER","populationDescription":"ITT population. Missing values were not imputed for this endpoint. Number in table represents the number of patients with prostate-specific antigen failure.","reportingStatus":"POSTED","timeFrame":"12 months","title":"Participants Grouped by Time to Prostate-specific Antigen Failure","type":"SECONDARY","unitOfMeasure":"participants"}